RecruitingNot Applicable

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

China1,400 participantsStarted 2026-03-15

Plain-language summary

This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among Overweight/Obese Individuals with Cardiometabolic Preconditions, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \>= 18 years, no gender restriction;
✓. Overweight and obesity: Body Mass Index (BMI) 24.0-32.4 kg/m\^2, or waist circumference \>= 90 cm for males and \>= 85 cm for females;
✓. Presence of at least one metabolic high-risk state among prehypertension, prediabetes, or borderline elevated blood lipids, and without a diagnosis of hypertension, diabetes mellitus, or dyslipidemia:

Exclusion criteria

✕. Secondary obesity diagnosed by doctors in secondary or higher-level medical institutions;
✕. Cardiovascular and cerebrovascular diseases, including myocardial infarction, stroke, heart failure, arrhythmia; or having received coronary intervention therapy, cardiac surgery, etc.; or with a 10-year high risk of cardiovascular disease;
✕. Diseases seriously affecting survival, such as malignant tumors, AIDS, hepatic and renal failure;
✕. Pregnancy, lactation period, or women who may become pregnant within one year;
✕. History of severe neuropsychiatric diseases with potential cognitive or communication impairments, such as dementia, Alzheimer's disease, Parkinson's syndrome;
✕. Individuals with limited daily mobility;
✕. Individuals undergoing or planning to receive weight loss through surgery, medication, or other methods;
✕. Currently participating in other lifestyle intervention-related trials.

What they're measuring

Change in Life's Essential 8 risk score

Timeframe: Baseline and 6 months after intervention

Trial details

NCT IDNCT07372729

SponsorBeijing Anzhen Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-15

Contact for this trial

wei wang, PhD

01081997731 wangw917@126.com

View on ClinicalTrials.gov More Prehypertension trials